We’re on the brink of a breakthrough. Our study is one step away from introducing a FDA-approved adult migraine treatment to children. Help us cross the finish line.
Migraines, debilitating and persistent, affect around 15% of adults. However, they don’t spare the young. Children, particularly those below 15 years, experience migraines that could be either bilateral or unilateral and non-throbbing. Symptoms include a pallid, sickly appearance, dizziness, blurred vision, fever, nausea, and vomiting. These young migraineurs, from as early as 7 years, may also avoid light (photophobia), noise (phonophobia), strong odors, and movement.
Research Works invites children and adolescents to join us in an exciting, compensated investigational trial based in New Orleans, Louisiana. We’re studying the effects of rimegepant, an FDA-approved adult migraine treatment.
Our clinical trial aims to test this adult-approved medication’s efficacy and safety in treating acute migraines in children and teens compared to a placebo. We’ll be involving 1,440 participants in total – approximately 1,200 adolescents and 240 children under 12. We’re specifically examining rimegepant’s safety in acute migraine treatment among the pediatric population.